Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 4/20 | 0.43 |
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15062845 | 0.85 | AKR1C3 (0.52) | AKR1C3AKR1C1AKR1C2PPARGPPARD | |
| SCHEMBL3095109 | 0.81 | AKR1C3 (0.57) | AKR1C3AKR1C1AKR1C2PPARGPPARD | |
| SCHEMBL3096000 | 0.80 | AKR1C3 (0.49) | AKR1C3AKR1C1AKR1C2PPARGPPARD | |
| SCHEMBL3091181 | 0.78 | BDKRB1 (0.47) | SMN1; SMN2MET | |
| SCHEMBL6446298 | 0.72 | KMT2A (0.62) | AKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL14591320 | 0.71 | MEN1 (0.66) | AKR1C3AKR1C1AKR1C2LMNAHTR6 | |
| SCHEMBL25734243 | 0.69 | ALDH1A1 (0.43) | AKR1C3AKR1C1AKR1C2PPARGPPARD | |
| SCHEMBL14473583 | 0.69 | ALDH1A1 (0.52) | LMNASMN1; SMN2CCR1 | |
| SCHEMBL2957547 | 0.69 | HTT (0.56) | LMNA | |
| SCHEMBL5242582 | 0.68 | AKR1C3 (0.58) | AKR1C3AKR1C1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393812-B1 | SUBSTITUTED SPIROAMIDES AS B1R-MODULATORS | GRUENENTHAL GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234340-A1 | Substituted Spiroamide Compounds | BDKRB1, BDKRB2, AVPR1B | AKR1C3 194/4885AKR1C1 201/4885AKR1C2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.